University of Maryland Greenebaum Comprehensive Cancer Center Joins the Big Ten Cancer Research Consortium

January 21, 2020

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has joined the Big Ten Cancer Research Consortium (Big Ten CRC). The consortium’s membership now includes the cancer centers of all Big Ten universities.

The Big Ten CRC was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. More than 300 researchers are currently active in Big Ten CRC Clinical Trial Working Groups, where researchers present their study concepts, receive valuable scientific feedback and identify participating institutions to open their studies. To date, the consortium has launched 25 clinical trials and enrolled more than 500 patient volunteers.

“We are delighted to join the Big Ten Cancer Research Consortium and look forward to forging new research partnerships with colleagues at other top academic institutions who share our commitment to developing effective new treatments for patients and ultimately defeating cancer,” said UMGCCC Director Kevin J. Cullen, MD., the Marlene and Stewart Greenebaum Distinguished Professor in Oncology at the University of Maryland School of Medicine. “Membership in the consortium offers our investigators a tremendous opportunity for collaboration.”

UMGCCC offers innovative approaches to diagnosing and treating all types of cancer, conducts cutting-edge research to bring the latest advances in cancer treatment directly to patients in Maryland and beyond, and provides cancer screening and patient education services. It is one of 51 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, recognized for its excellence in patient care and multidisciplinary translational research program.

View more information about UMGCCC’s research program.